- 2021 Speakers
- 2021 Agenda
- 2021 Expo
- Contact us
Wednesday, 13 October 2021
Registration and refreshments
09:30Private markets outlook: Navigating a new era
Led by China, Asia Pacific looks set to spearhead the global post-COVID recovery. Despite geopolitical tensions with some Western nations, China has already called on global partners to help revive key economies. Indeed, the launch of the Regional Comprehensive Economic Partnership (RCEP) – the world’s largest free trade bloc, comprising 15 major Asia Pacific nations – will boost business and investment activities Asia wide. Our panel of renowned experts will analyse the economic outlook and discuss how the private investment landscape might change in the next three to five years.
- How will the US change of leadership affect policies towards Asia, and China in particular?
- How will macro developments affect the global flow of capital and investment activity?
- Which sectors and geographies will offer the most attractive opportunities, and how can foreign investors tap into China’s market liberalization?
- Can we expect any fundamental shifts in LP strategies towards Asia and China?
11:1520 years of private equity in China: Past, present, and future
In 2001, AVCJ launched the first international private equity and venture event focused on the nascent Chinese industry, bringing many first-time investors from across the globe to Beijing. From an intimate gathering of friends to the much-anticipated event it is today, AVCJ China has supported, mirrored, and grown with the Mainland GP and LP community. This panel shares the perspectives of experienced private equity managers that have weathered the cycles and navigated their funds to great success.
- How has the people, skillset and the industry evolved in the past 20 years?
- As the GP community diversify their deal focus, their fund size and regional focus, which strategies have consistently delivered outsized returns?
- What do GPs need to do to ensure a sustainable ecosystem in China?
- How has their firms responded to the increasingly important role of diversity, ESG and corporate governance?
- What will be the major challenges that the industry will face in the coming years, and how can participants best prepare themselves?
11:55In pursuit of alpha: Lessons in value creation
Faced with slowing global growth and an increasingly complex business environment, value creation has become essential to generating alpha. From creating the right business models to capture the potential of new technologies, to implementing transparent corporate governance to tackle black swan events, GPs need to retool their capabilities. Only those able to transform themselves and their investees will outperform. Our panel of experts ask:
- What kinds of interventions work best in China? What has and has not changed post-COVID-19?
- How is digital transformation boosting value creation?
- What goes into the best operating team?
- Corporate governance and fraud management – what are the lessons learnt?
14:10The consumer story: Still on fire
China’s GDP by purchasing power parity (PPP) reached US25.27 trillion, the world’s largest, in 2020 according to International Monetary Fund. Investors both at home and abroad are once again banking on China’s 1.4 billion consumers to reboot growth. Rapid digital developments have unlocked new behaviours, communication channels, and expectations of brand experience, pushing investors towards new frontiers. New consumer-focused funds are successfully engaging with this increasingly complicated sector. Prominent investors and experts will delve into the consumer space and debate strategies that can best access the opportunities.
- What are the new consumer trends driving deal flows?
- What are the proven strategies, from deal-sourcing to value creation and exits?
- How do overseas investors compete in this very local sector?
- Will we see more consumer-specialist GPs? What niches can they fill?
15:15Capturing the resurgence of healthcare
China’s healthcare industry has seen a renewed surge of investor interest in light of the pandemic, aging demographic shifts and regulatory reforms. According to Mergermarket data, the value of 2020 healthcare deals in China more than doubled from $8.3 billion to $19.6 billion. In terms of segments, biotech and pharmaceutical deals were the most popular , with a combined deal value of $14.4 billion. As momentum for Chinese healthcare continues to pick up, get the insight on the most exciting opportunities and fastest growing trends from our panel of experts.
- What are the latest regulatory changes supporting the healthcare industry?
- Which sub-segments are currently most attractive for GPs? Biotech, medtech, pharmaceuticals?
- What emerging innovations in healthcare technology that investor should pay attention to?
- Is there too much money chasing deals in the sector?
16:15Technology: Where are China’s unicorns?
China’s technology sector is growing increasingly polarised. At one end of the spectrum, established unicorns continue to raise capital at elevated valuations from an array of investors. At the other, once-star start-ups that are falling out of favour, with much talk of down rounds and dirty term sheets. Post-COVID-19, investors are being more selective about cash-burning B2C players and placing greater emphasis on B2B. Our expert panellists identify the future category killers in China’s digital economy.
- Which segments are most likely to see down rounds?
- How is investor appetite changing for late-stage rounds?
- Will enterprise services evolve into a sustainable industry?
- What do tighter regulations mean for unicorns and IPO listing?
End of Day 1
An error occurred trying to play the stream. Please reload the page and try again.Close